ChemicalBook > CAS DataBase List > Rosmantuzumab
Rosmantuzumab
- Product Name
- Rosmantuzumab
- CAS No.
- 1684393-04-1
- Chemical Name
- Rosmantuzumab
- Synonyms
- OMP-131R10;Rosmantuzumab;Rosmantuzumab (anti-RSPO3);Research Grade Rosmantuzumab;Research Grade Rosmantuzumab (DHJ51101)
- CBNumber
- CB58081006
- Formula Weight
- 0
- MOL File
- Mol file
More
Less
Rosmantuzumab Property
- form
- Liquid
- color
- Colorless to light yellow
More
Less
Rosmantuzumab Chemical Properties,Usage,Production
Uses
Rosmantuzumab (OMP-131R10) is an anti-R-spondin 3 (RSPO3) humanized monoclonal antibody. Rosmantuzumab can be used for the research of advanced telapsed and refractory solid tumors[1].
in vivo
Rosmantuzumab (25 mg/kg; i.p., once a week for 4 weeks) significantly protects the animals from developing liver fibrosis[1]. Rosmantuzumab (25 mg/kg; i.p., once for two weeks, for total 6 weeks) significantly inhibits skin thickness, collagen deposition, and number of α-SMA positive cells in bleomycin-induced lung fibrosis mouse models[1].
| Animal Model: | Male C57B1/6J CCl4 liver fibrosis mouse models[1] |
| Dosage: | 25 mg/kg |
| Administration: | Intraperitoneal injection; 25 mg/kg, once a week for 4 weeks |
| Result: | Significantly decreased collagen I and collagen III mRNAs, and inhibits β-catenin cytoplasmic and nuclear translocation. |
References
[1] Zhang M, et al. Targeting the Wnt signaling pathway through R-spondin 3 identifies an anti-fibrosis treatment strategy for multiple organs. PLoS One. 2020 Mar 11;15(3):e0229445. DOI:10.1371/journal.pone.0229445
Rosmantuzumab Preparation Products And Raw materials
Raw materials
Preparation Products
More
Less
Rosmantuzumab Suppliers
- Tel
- 021-61312847; 18021002903
- Fax
- QQ:3008007432
- 3008007409@qq.com
- Country
- China
- ProdList
- 71826
- Advantage
- 60
- Tel
- 177-54423994 17754423994
- Fax
- QQ:2853530913
- 2853530910@QQ.com
- Country
- China
- ProdList
- 8000
- Advantage
- 62
- Tel
- 15817493340
- 981810490@qq.com
- Country
- China
- ProdList
- 1566
- Advantage
- 58
- Tel
- 027-65317797 15926423062
- Fax
- QQ:422450190
- 422450190@qq.com
- Country
- China
- ProdList
- 10308
- Advantage
- 58
- Tel
- 4008200310
- marketing@tsbiochem.com
- Country
- China
- ProdList
- 24961
- Advantage
- 58
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com
- Country
- China
- ProdList
- 9868
- Advantage
- 58
- Tel
- 13720134139 086-15871494362 13720134139
- orders@jknbiochem.com
- Country
- China
- ProdList
- 6762
- Advantage
- 58
- Tel
- 021-65675885 18964387627
- customer_service@efebio.com
- Country
- China
- ProdList
- 11973
- Advantage
- 58
- Tel
- 400-6206333 13167063860
- anhua.mao@aladdin-e.com
- Country
- China
- ProdList
- 48457
- Advantage
- 58
- Tel
- 0731-13823398 15111215862
- 313359644@qq.com
- Country
- China
- ProdList
- 4161
- Advantage
- 58
- Tel
- 17316404525 17316404525
- 209533805@qq.com
- Country
- China
- ProdList
- 9763
- Advantage
- 58
- Tel
- 0573-83568680 18057391398
- 3956524501@qq.com
- Country
- China
- ProdList
- 1442
- Advantage
- 58
- Tel
- 027-87008169 17762441161
- info@atagenix.com
- Country
- China
- ProdList
- 10001
- Advantage
- 58
- Tel
- 400-821-026
- Sales@sangon.com
- Country
- China
- ProdList
- 6710
- Advantage
- 58
- Tel
- 33175446423
- support@antibodysystem.com
- Country
- China
- ProdList
- 6739
- Advantage
- 58
- Tel
- 51288865780
- sales@biosynth.com
- Country
- China
- ProdList
- 6051
- Advantage
- 58
- Tel
- 400-668-6834
- info@selleck.cn
- Country
- China
- ProdList
- 6071
- Advantage
- 58
- Tel
- 9785721070
- info@cellsciences.com
- Country
- China
- ProdList
- 6308
- Advantage
- 58
- Tel
- 18818417021
- Country
- CHINA
- ProdList
- 127
- Advantage
- 58
- Tel
- 18028747627
- Country
- CHINA
- ProdList
- 191
- Advantage
- 58
- Tel
- 18926165828
- Country
- CHINA
- ProdList
- 198
- Advantage
- 58
- Tel
- --
- Fax
- --
- Proteintech-CN@ptglab.com
- Country
- CHINA
- ProdList
- 6290
- Advantage
- 58
1684393-04-1, RosmantuzumabRelated Search:
Samalizumab
Tarcocimab
Placulumab
Ontamalimab
Manfidokimab
Bermekimab
Tirnovetmab
Garadacimab
reslizumab
Lutikizumab